Featured Research

from universities, journals, and other organizations

Drug shows promise for Huntington's disease

Date:
February 9, 2010
Source:
University of Rochester Medical Center
Summary:
An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition.

An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published in the Archives of Neurology.

Related Articles


"This is the first clinical trial that has focused on what is perhaps the most disabling aspect of the disease," said University of Rochester Medical Center neurologist Karl Kieburtz, M.D., the lead author of the study. "While more investigation needs to be done, these results are encouraging and show, for the first time, a statistically significant benefit in terms of improved cognitive function in patients with Huntington's disease."

Huntington's disease is a progressive neurodegenerative disorder that impacts movement, behavior, cognition, and generally results in death within 20 years of the disease's onset. The disease steadily erodes a person's memory and their ability to think and learn. Over time, this cognitive impairment contributes to the loss of the ability to work and perform the activities of daily life. There are no treatments current available that effectively alter the course of the disease or improve cognition.

It is believed that mitochondria -- the part of the cell that helps convert food to energy -- plays a role in the development of Huntington's disease. Lampridine stabilizes and enhances mitochondrial function, a result that has been shown to improve behavioral, cognitive, and functional outcomes in Alzheimer's disease. Scientists speculate that this may have the same effect in patients with Huntington's disease.

The investigators studied the impact of the drug on 91 patients over a 90 day period. Half were given the drug and the other half a placebo. The patients were then evaluated using a cognitive tool called the Mini-Mental State Examination. This exam -- which is used by clinicians to evaluate the stage and severity of dementia and Alzheimer's disease -- consists of series of questions used to test an individual's orientation, memory, and ability to follow commands. The researchers found that the drug on average improved the scores of people taking the drug vs. those who received the placebo.

Dimebon is being developed by Medivation, Inc., a San Francisco-based pharmaceutical company which funded the study. The drug is also being testing in patients with Alzheimer's disease. In July of last year, Medivation and Pfizer, Inc. launched a Phase 3 clinical trial of the drug for Huntington's disease. The study, called the Horizon Trial, is being conducted in sites throughout North America, Australia, and Europe. Kieburtz is the principal investigator of the Horizon Trial.


Story Source:

The above story is based on materials provided by University of Rochester Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Karl Kieburtz; Michael P. McDermott; Tiffini S. Voss; Jody Corey-Bloom; Lisa M. Deuel; E. Ray Dorsey; Stewart Factor; Michael D. Geschwind; Karen Hodgeman; Elise Kayson; Sarah Noonberg; Michael Pourfar; Karen Rabinowitz; Bernard Ravina; Juan Sanchez-Ramos; Lynn Seely; Francis Walker; Andrew Feigin; and The Dimebon in Subjects With Huntington Disease (DIMOND) Investigators of the Huntington Study Group. A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease. Arch Neurol, 2010; 67 (2): 154-160 [link]

Cite This Page:

University of Rochester Medical Center. "Drug shows promise for Huntington's disease." ScienceDaily. ScienceDaily, 9 February 2010. <www.sciencedaily.com/releases/2010/02/100208185347.htm>.
University of Rochester Medical Center. (2010, February 9). Drug shows promise for Huntington's disease. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2010/02/100208185347.htm
University of Rochester Medical Center. "Drug shows promise for Huntington's disease." ScienceDaily. www.sciencedaily.com/releases/2010/02/100208185347.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Mind & Brain News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com
Prenatal Exposure To Pollution Might Increase Autism Risk

Prenatal Exposure To Pollution Might Increase Autism Risk

Newsy (Dec. 18, 2014) Harvard researchers found children whose mothers were exposed to high pollution levels in the third trimester were twice as likely to develop autism. Video provided by Newsy
Powered by NewsLook.com
Yoga Could Be As Beneficial For The Heart As Walking, Biking

Yoga Could Be As Beneficial For The Heart As Walking, Biking

Newsy (Dec. 17, 2014) Yoga can help your weight, blood pressure, cholesterol and heart just as much as biking and walking does, a new study suggests. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins